# Olympus Acquires BioProtect for $270M to Expand Oncology Implant Portfolio

> ma · REPORTED · 2026-05-26

Olympus signed a definitive agreement to acquire BioProtect for $270 million, adding BioProtect's biodegradable Balloon Spacer implant system — which protects healthy rectal tissue during prostate cancer radiation therapy — to its urology and oncology portfolio. The device has been used in more than 11,000 procedures worldwide since its commercial launch.

About Olympus / BioProtect: BioProtect develops a biodegradable balloon implant system that creates temporary physical spacing between the prostate and rectum during radiation therapy for prostate cancer, reducing healthy tissue damage and naturally resorbing after treatment.

- Company: Olympus / BioProtect
- Sector: oncology
- Primary source: https://www.olympus-global.com/news/2026/nr03020.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.